Identification of indole inhibitors of human hematopoietic prostaglandin D2 synthase (hH-PGDS)

  • Bioorg Med Chem Lett. 2015 Jun 15;25(12):2496-500. doi: 10.1016/j.bmcl.2015.04.065.
Fredrik Edfeldt  1 ,  Johan Evenäs  2 ,  Matti Lepistö  2 ,  Alison Ward  2 ,  Jens Petersen  3 ,  Lisa Wissler  3 ,  Mattias Rohman  3 ,  Ulf Sivars  2 ,  Karin Svensson  2 ,  Matthew Perry  2 ,  Isabella Feierberg  3 ,  Xiao-Hong Zhou  2 ,  Thomas Hansson  2 ,  Frank Narjes  2
Affiliations
  • 1. Discovery Sciences, Innovative Medicines, AstraZeneca R&D, 431 83 Molndal, Sweden. Electronic address: [email protected].
  • 2. Respiratory, Inflammation and Autoimmunity, Innovative Medicines, AstraZeneca R&D, 431 83 Molndal, Sweden.
  • 3. Discovery Sciences, Innovative Medicines, AstraZeneca R&D, 431 83 Molndal, Sweden.
Abstract

Human H-PGDS has shown promise as a potential target for anti-allergic and anti-inflammatory drugs. Here we describe the discovery of a novel class of indole inhibitors, identified through focused screening of 42,000 compounds and evaluated using a series of hit validation assays that included fluorescence polarization binding, 1D NMR, ITC and chromogenic enzymatic assays. Compounds with low nanomolar potency, favorable physico-chemical properties and inhibitory activity in human mast cells have been identified. In addition, our studies suggest that the active site of hH-PGDS can accommodate larger structural diversity than previously thought, such as the introduction of polar groups in the inner part of the binding pocket.

Keywords
Focused screening; Hit validation; Indole; PGDS inhibitors; Prostaglandin D(2) synthase.